Volume 11, Issue 3 (9-2022)                   JCHR 2022, 11(3): 210-218 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdellahi L, Hejazi S H, Amirmozafari N, Sotoodehnejadnematalahi F. Frequency of Cutaneous Leishmaniasis and Complete Ulcer Healing in Patients Referred to Skin Diseases and Leishmaniasis Research Center, Isfahan, Iran from 2018 to 2019. JCHR 2022; 11 (3) :210-218
URL: http://jhr.ssu.ac.ir/article-1-723-en.html
1- Department of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2- Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. , hejazih12@gmail.com
3- Iran University of Medical Sciences, School of Medicine, Microbiology Department, Tehran, Iran.
Abstract:   (168 Views)
Introduction: Iran is one of the most important hot spots for cutaneous leishmaniasis (CL) in the world. To date, no studies have been done on both epidemiological aspects along with the length of the treatment course of CL. This study aimed to determine the relative frequency of CL in patients with suspected skin lesions and the duration of healing after treatment with different regimens.
Methods: This cross-sectional study was conducted on patients with CL referred to the skin diseases and leishmaniasis research center (SDLRC) in Isfahan during the years 2018 to 2019. Among 389 patients with suspected skin lesions, 150 cases were included with proven CL. Information such as age, sex, education, location, size of the lesion, duration of treatment, and the rate of recovery were recorded. SPSS software version 20 was used for data analysis, the chi-square, Fisher´s Exact, and one Way ANOVA tests were used with a significant level of p < 0.05.
Results: Among 350 admitted cases, 150 cases were CL. positive (42.85%). The rate of complete recovery was higher in cases with an average age of 33.55 ±18.9 years, but these differences were not statistically significant (P =0.077). There was 34 cases more than the other groups in this range of age. ( The rate of complete recovery in patients with a history of migration to endemic areas was higher than in patients without a history of migration (P = 0.81)). The rate of complete recovery in patients whose means treatment duration was 59.03 ± 41.43 days was higher than other recovery periods (P = 0.23).
Conclusion: The rate of complete recovery was higher in adult cases than the other groups. In this study, it was proved that the rate of recovery of patients had the significant relationship with the average duration of treatment.
Full-Text [PDF 683 kb]   (64 Downloads) |   |   Full-Text (HTML)  (24 Views)  
Review: Research | Subject: Health care management
Received: 2021/01/2 | Accepted: 2022/09/19 | Published: 2022/10/19

1. 1. Jaffary F, Abdellahi L, Nilforoushzaheh MA. Review of the prevalence and causes of antimony compound resistance in different societies review article. Tehran University Medical Journal TUMS Publications. 2017;75(6):399-407.
2. Aghaei Afshar A, Hojjat F, Yaghoobi‐Ershadi MR, Rassi Y, Akhavan AA, Gorouhi MA, Yousefi S, Hanafi‐Bojd AA. Modeling and evaluating the risk of zoonotic CL in selected areas of Kerman Province, south of Iran. Transboundary and emerging diseases. 2020 May;67(3):1271-83. [DOI:10.1111/tbed.13465]
3. Ahmadi NA, Modiri M, Mamdohi S. First survey of cutaneous leishmaniasis in Borujerd county, western Islamic Republic of Iran. East Mediterr Health J. 2013;19:847-53. doi: 10.26719/2013.19.10.847. PubMed PMID: 24313148. [DOI:10.26719/2013.19.10.847]
4. Nassif PW, DE MELLO TFP, NAVASCONI TR, Mota CA, Demarchi IG, ARISTIDES SMA, et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology. 2017;144(8):995. [DOI:10.1017/S0031182017000385]
5. Alten B, Maia C, Afonso MO, Campino L, Jiménez M, González E, et al. Seasonal dynamics of phlebotomine sand fly species proven vectors of Mediterranean leishmaniasis caused by Leishmania infantum. PLoS Negl Trop Dis. 2016;10:e0004458. [DOI:10.1371/journal.pntd.0004458]
6. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndrome and treatment. QJM. 2014;107(1):7-14. https://doi.org/10.1093/qjmed/hct116 [DOI:10.1093/qjmed/htc116.]
7. World Health Organization. Leishmaniasis. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/ leishmaniasis [Accessed 14 August 2019].
8. World Health Organization (WHO). Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: World Health Organization; 2010.
9. Ershadi M-RY, Zahraei-Ramazani A-R, Akhavan A-A, Jalali-Zand A-R, Abdoli H, Nadim A. Rodent control operations against zoonotic cutaneous leishmaniasis in rural Iran. Annals of Saudi medicine. 2005;25(4):309-12. [DOI:10.5144/0256-4947.2005.309]
10. Nilforoushzadeh M, Shirani-Bidabadi L, Hosseini S, Fadaei-Nobari R, Jaffary F. The epidemiology of cutaneous leishmaniasis in Isfahan province, Iran, during 2001-2011. Journal of Isfahan Medical School. 2015;32(315):2241-51. [DOI:10.17795/jssc23303]
11. Razavi TSV. Cutaneous leishmaniasis susceptibility mapping using multi-criteria decision-making techniques analytic hierarchy process (AHP) and analytic network process (ANP). 2018. Journal of Research in Environmental Health. 2018;3(4):276-286.
12. Khademvatan S, Salmanzadeh S, Foroutan-Rad M, Bigdeli S, Hedayati-Rad F, Saki J, et al. Spatial distribution and epidemiological features of cutaneous leishmaniasis in southwest of Iran. Alexandria Journal of Medicine. 2017;53(1):93-8. [DOI:10.1016/j.ajme.2016.03.001]
13. Valero NN, Uriarte M. Environmental and socioeconomic risk factors associated with visceral and CL: a systematic review. Parasitology research. 2020 Feb;119(2):365-84. [DOI:10.1007/s00436-019-06575-5]
14. Mohammadi J, Faramarzi H, Ameri A, Bakhtiari H. Epidemiological Study of CL in Marvdasht, Iran, 2017. Armaghane Danesh. 2018;23(4):488-98.
15. de Souza RAF, Andreoli RV, Kayano MT, Carvalho AL (2015) American CL cases in the Metropolitan region of Manaus, Brazil: association with climate variables over time. Geospatial Health 10:40-47. [DOI:10.4081/gh.2015.314]
16. Barati H, Barati M, Lotfi MH. Epidemiological study of cutaneous leishmaniasis in Khatam, Yazd province, 2004-2013. Paramedical Sciences and Military Health. 2015;10(2):1-5.
17. Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional carbon dioxide laser plus glucantime on cutaneous leishmaniasis lesions. Dermatology research and practice. 2016;2016. [DOI:10.1155/2016/6462804]
18. Nejati J, Mojadam M, Hanafi Bojd AA, Keyhani A, Habibi Nodeh F. An epidemiological study of cutaneous leishmaniasis in Andimeshk (2005-2010). scientific journal of ilam university of medical sciences. 2014;21(7):94-101.
19. Piroozi B, Moradi G, Alinia C, Mohamadi P, Gouya MM, Nabavi M, Gharachorloo F, ERFAN MB, Shirzadi MR. Incidence, burden, and trend of CL over four decades in Iran. Iranian Journal of Public Health. 2019 Mar 4;48(Supple 1):28-35.
20. Ayaz MM, Nazir MM, Ullah N, Zaman A, Akbar A, Zeeshan M, Hussain Z, Naz S, Zheng Y, Javed A, Lindsay DS. CL in the Metropolitan City of Multan, Pakistan, a neglected tropical disease. Journal of medical entomology. 2018 Jun 28;55(4):1040-2. [DOI:10.1093/jme/tjy003]
21. Jafarnejad A, Jamshidi F, Deghan A. Evaluation of CL in the city of Lamerd in2004-2014. Medical Journal of Mashhad University of Medical Sciences. 2017;60(1):376-82.
22. Roghani AR, Yasemi MR, Jalilian M, Abdi J, Rezai Tavirani K. Epidemiology of CL in Ilam province. Research in Medicine. 2013;36(5):50-3.
23. Ghohe HP, Pagheh AS, Fakhar M, Tavakoli G, Nazar E, Kiani M. Molecular identification of Leishmania species isolated from patients with cutaneous leishmaniasis in Pakdasht district, Iran, 2009-2014. J Mazandaran Univ Med Sci. 2016;26(143):216-21.
24. Alkhawajah A, Larbi E, Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Annals of Tropical Medicine & Parasitology. 1997;91(8):899-905. [DOI:10.1080/00034983.1997.11813217]
25. Sadeghian G, Shirani BL, Ziaei H, Hejazi S, Zolfaghari BA. Evaluation of Glucantime activity in cutaneous leishmaniasis lesion contaminated with secondary bacterial infection compared with non-infected lesions. Annals of Millitary and Health Science Research. 2010;8( 1):6-10. [DOI:10.4103/0019-5154.77549]
26. Nilforoushzadeh MA, Jaffary F, Derakhshan R, Haftbaradaran E. Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis: a randomized clinical trial. Journal of Skin and Stem Cell. 2014;1(1). [DOI:10.17795/jssc16633]
27. H M, M G. Evaluation of epidemiologic causes in cutaneous leishmaniasis patients referred to the health care center of Mashhad Moghadam province from 2008 to 2013. . Journal of Medical science. 2017;22(7):1-3.
28. Lotfi M.H., Noori S., Taj Firouze A.A., Fallahzadeh H., Ayatollahi J. Epidemiological Study of an Outbreak of CL in Five Endemic Foci, Yazd Province, Iran March 2015-March 2016. Journal of Community Health Research 2017; 6(2): 77-84.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Community Health Research

Designed & Developed by : Yektaweb